# Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer

> **NCT03284957** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 136 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Amcenestrant
- **DRUG:** Palbociclib
- **DRUG:** Alpelisib
- **DRUG:** Everolimus
- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT03284957
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-20
- **Primary completion:** 2024-11-08
- **Final completion:** 2024-11-08
- **Target enrollment:** 136 (ACTUAL)
- **Why stopped:** Sponsor decision to prematurely stop the study, not linked to any safety concern.
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03284957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03284957, "Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03284957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*